SPECIALTY / DIRECT CATALOG PRICING
PT-141
PT-141 is bremelanotide, a cyclic melanocortin-receptor agonist. The name identifies the active peptide but not a particular salt, formulation, or approved finished drug.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 1
- Catalog class
- Specialty
- 10 mg$30.00 · AvailableSelect
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
PT-141 is bremelanotide, a cyclic melanocortin-receptor agonist. The name identifies the active peptide but not a particular salt, formulation, or approved finished drug.
The specialty classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Specialty
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 1 format currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
PT-141 is bremelanotide, a cyclic melanocortin-receptor agonist. The name identifies the active peptide but not a particular salt, formulation, or approved finished drug.
- Research covered
- FDA labeling documents an approved, manufacturer-specific bremelanotide injection and summarizes its clinical-development evidence for a narrowly defined population and indication.
- Important limit
- PSC's 10 mg research vial is not the FDA-approved finished product described in the label. The label does not verify this vendor material and should not be repurposed as administration guidance for it.
- Authoritative sources
FACTUAL FAQ
PT-141 catalog questions
What formats are currently listed?
10 mg. Current price and stock state appear above.
What did researchers study?
FDA labeling documents an approved, manufacturer-specific bremelanotide injection and summarizes its clinical-development evidence for a narrowly defined population and indication.
What is the most important evidence limit?
PSC's 10 mg research vial is not the FDA-approved finished product described in the label. The label does not verify this vendor material and should not be repurposed as administration guidance for it.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
